NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

NovaBridge BiosciencesNASDAQ: NBP

Weighted Avg Shares · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares declines year over year

Q4 FY2025 weighted avg shares of 50.17M shares fell 38.4% year over year, behind the -12.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at -20.4% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -38.4% toward the trailing-twelve-month pace of -12.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
50.17M+14.3% QoQ
Last fiscal yearDec 2025
41.64M-48.7% YoY
LTMSep 2025
72.17M-12.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-38.4%——
1 year-48.7%——
3-year CAGR-20.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
41.64M USD
Year-over-year change
—

Weighted Avg Shares vs competitors

How NBP compares with its peers on the latest reported figures

  • NBP's LTM Sep 2025 weighted avg shares of 72.17M shares is the 5th highest of the 11 companies compared; the peer median is 63.63M shares.
  • Its year-over-year change of -12.1% is the lowest of 10, against a peer median of +16.1%.
  • Over three fiscal years its annual growth of -20.4% compares with a peer median of +22.2%.
NBP Competitors Peer median
Weighted Avg Shares for NBP and competitors
Company Period LTM YoY 3-year CAGR
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 202684.87M +21.1%+8.2%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -12.1%-20.4%
GALTGalectin Therapeutics Inc.LTM Mar 202664.33M +2.7%+2.5%
AURAAura Biosciences, Inc.LTM Mar 202662.93M +26.5%+26.3%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
DSGNDesign Therapeutics, Inc.LTM Mar 202658.14M +2.6%+1.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
Peer median (excluding NBP) 63.63M+16.1%+22.2%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Revenue88.03M(10.7M)4.49M00
Cost of Revenue46.43M0000
Gross Profit41.59M(10.7M)4.49M00
Gross Margin47.3%100.0%100.0%——
Research & Development190.29M155.51M114.36M158.9M8.99M
Selling, General & Admin899.94M199.88M63.91M216.46M4.48M
Operating Expenses2.11B355.38M515.65M375.36M13.48M
Depreciation & Amortization13.78M1.42M3.37M1.91M122.37K
EBITDA(2.06B)(51.23M)(344.25M)(373.45M)(13.35M)
EBITDA Margin-2337.4%478.9%-7674.2%——
Operating Income(2.07B)(366.08M)(511.16M)(375.36M)(13.48M)
Operating Margin-2353.1%3422.2%-11395.1%——
Interest Income21.33M4.95M7.3M54.64M1.09M
Interest Expense00101.85K00
Other Income / Expenses(260.73M)(607.09M)(954.53M)12.63M847.61K
Income Before Tax(2.33B)(973.17M)(1.47B)(362.73M)(12.63M)
Pre-Tax Margin-2649.3%9097.4%-32674.0%——
Income Tax Expense(494.81K)710.39K(1.26B)00
Net Income(2.33B)(2.51B)(1.47B)(162.26M)(6.61M)
Net Margin-2648.7%23438.9%-32674.0%——
EPS (Basic)(30.70)(30.38)(17.62)(4.46)(0.16)
EPS (Diluted)(30.68)(30.38)(17.62)(4.46)(0.16)
Weighted Avg Shares75.93M82.52M83.19M81.19M41.64M
Weighted Avg Shares (Diluted)75.96M82.52M83.23M81.19M41.64M

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.